title: [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
abstract: The role of cytoreductive nephrectomy in the current era of targeted therapy remains unknown. Two prospective randomized phase III trials (CARMENA and SURTIME) are now opened to evaluate the efficacy of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. So far it is not well known who will and who will not benefit from such surgery.
authors.forename: A K
authors.initials: AK
authors.lastname: Nosov
authors.forename: A V
authors.initials: AV
authors.lastname: Novik
authors.forename: A V
authors.initials: AV
authors.lastname: Vorobiev
authors.forename: E E
authors.initials: EE
authors.lastname: Samartseva
authors.forename: S A
authors.initials: SA
authors.lastname: Reva
authors.forename: I A
authors.initials: IA
authors.lastname: Baldueva
authors.forename: P A
authors.initials: PA
authors.lastname: Lushina
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D065426:Cytoreduction Surgical Procedures; D019317:Evidence-Based Medicine; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D009392:Nephrectomy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents